RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis

计划入组 120 人 · 首次发布于 2024 年 10 月 16 日

Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour

计划入组 12 人 · 首次发布于 2022 年 9 月 15 日

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

计划入组 56 人 · 首次发布于 2015 年 6 月 12 日

Denosumab(Prolia, Xgeva, Wyost, Jubbonti, Stoboclo, Obodence, Osenvelt, Xbryk, Jubereq, Osvyrti, Evfraxy, Vevzuo, Junod, Conexxence, Yaxwer, Denbrayce, Izamby, Rolcya, Enwylma, Bilprevda, Bomyntra, Zvogra, Degevma, Ponlimsi, Denosumab Intas, Bildyos, Osqay)

Rx

CXCR4 (Ligand)

RANKL-RANK interaction inhibitors (osteoporosis)

Ligand Pharmaceuticals

United States

CEL-SCI

United States

Eledon Pharmaceuticals

United States

EMA Accepts Alvotech's Biosimilar AVT03 for Prolia and Xgeva

Samsung Bioepis Advances Denosumab Biosimilar (SB16) for Osteoporosis and Oncology Indications

FDA Approves Samsung Bioepis' Denosumab Biosimilars for Bone Health Conditions